Devdatt Kurdikar: Good morning and thanks for taking the time to hitch us. Over the previous yr, and notably since we reported our fiscal yr 2025 outcomes, we now have continued to make significant progress executing our strategic roadmap we outlined at our Investor Day final yr. As a reminder, that roadmap is constructed round a phased method consisting of standing up the group, seeding development, and finally remodeling the corporate right into a broad-based medical provides firm which serves continual care sufferers and drug supply companions. The stand-up part was centered on changing into a totally unbiased firm by constructing our personal methods, provide chain, and business capabilities whereas protecting the bottom enterprise secure.
Fiscal yr 2025 largely marked the completion of that part with the operationalization of our personal ERP, distribution, and shared companies infrastructure permitting for the whole migration of our income into our methods and the profitable exit of all TSAs and LSAs. I’m happy to say that we had been capable of full the stand-up part and all of the related complicated initiatives whereas protecting our fixed forex income secure. That work behind us, we at the moment are firmly within the seed development part. That is the place the corporate’s focus is now. This part’s objectives give attention to staying aggressive within the core, selectively increasing the portfolio in areas that leverage our present strengths, and constructing monetary flexibility by way of disciplined capital allocation.
The priorities on this part are supposed to place Embecta over time as a broader medical provides firm and a drug supply companion, constructing on our basis as a frontrunner in international insulin supply. One essential aspect of strengthening the core has been our model transition. This initiative isn’t a change to the product or product names. It’s a change to packaging and branding that establishes Embecta as an unbiased firm within the minds of sufferers, healthcare professionals, and channel companions. We’ve got taken a disciplined phased method. As of right this moment, greater than 95% of US and Canadian has transitioned to the Embecta model. With North America largely full, we now have been executing the subsequent part globally.
Transitions are underway in choose worldwide markets and we anticipate most areas to be considerably full by the top of calendar yr 2026. We proceed to exhibit a powerful dedication to making sure broad and most popular entry to our merchandise for sufferers, notably throughout the Medicare Half D channel, which stays an essential and rising phase of the payer market serving senior residents who characterize a excessive share of individuals residing with diabetes. Efficient January 2026, we contracted with a further Medicare Half D payer for unique entry to our product. As well as, we renewed our benefit formulary entry with the highest three Medicare Half D payers that we had present relationships with.
Collectively, these actions additional strengthen our enterprise, supporting secure entry and share, and enhancing the long-term competitiveness of our portfolio. One other key space of focus within the seed development part is portfolio enlargement by way of market-appropriate pen needles and syringes. Our method right here is intentional. We’re leveraging what we already do properly to deal with segments the place there may be significant demand, however the place our share right this moment stays comparatively low. Since fiscal yr 2025, we now have moved from idea to execution. Product designs for these market-appropriate choices have been finalized. Manufacturing gear has been put in, and manufacturing validation is now underway.
With this basis in place, we’re progressing in the direction of anticipated regulatory submissions and ultimately business launches supported by go-to-market methods knowledgeable by greater than a century of expertise in insulin supply. We’ve got additionally continued to advance our GLP-1 technique, which we view as an extension of our core capabilities relatively than a departure from them. At present, we’re collaborating with greater than 30 pharmaceutical companions throughout varied phases of the gross sales cycle, primarily centered on co-packaging our pen needles with generic GLP-1 therapies. A couple of-third of those companions have already chosen us as a provider and have both executed contracts or are in contract negotiations, reflecting tangible progress past early-stage discussions.
A number of companions have signed agreements and positioned buy orders, and our pen needles are included in a number of partner-managed regulatory submissions. Whereas we don’t management the timing of regulatory approvals or launches, we stay operationally able to assist our companions as packages advance. Wanting forward, our companions are anticipating preliminary generic GLP-1 launches in markets similar to Canada, Brazil, China, and India, starting in calendar yr 2026, with extra rising markets anticipated to comply with over time. This expectation is in line with the latest public information report indicating that regulatory approvals for generic injectable semaglutide have been granted to some firms in India, with a number of producers getting ready for business launches following patent expirations in March 2026.
In parallel, we’re increasing the provision of consumer-friendly Embecta-branded small pack configurations in Canada and choose European markets. These codecs are designed for out-of-pocket clients, together with many GLP-1 customers, and permit us to take part within the class utilizing present manufacturing and business infrastructure. Just lately, there was a big quantity of stories associated to the event and launch of oral GLP-1 therapies. It must be famous that the launch of oral GLP-1s was anticipated and explicitly included in our assumptions underlying the estimated $100 million-plus alternative we had mentioned at our Analyst and Investor Day in Could 2025. Whereas it’s early within the adoption of oral GLP-1s, we proceed to imagine within the alternative as beforehand outlined.
Importantly, we anticipate to assist this incremental quantity inside our present manufacturing footprint and with out important incremental capital funding. We additionally anticipate this to assist engaging margin move by way of over time. Past generics, we’re additionally engaged in early-stage discussions with a number of branded pharmaceutical firms round co-packaging alternatives for medication in growth. Whereas these discussions are in early phases, they characterize potential past the chance we shared at our Investor Day final Could. Lastly, we stay centered on growing monetary flexibility. Following the numerous deleveraging achieved by way of fiscal yr 2025, we proceed to give attention to free money move technology and disciplined capital allocation to create strategic optionality as we progress by way of the seed development part.
In abstract, whereas fiscal yr 2025 marked the completion of our stand-up part, Embecta right this moment is targeted on execution, portfolio enlargement, and positioning the corporate for sturdy long-term development. With that context, let me now overview our income efficiency for the primary quarter. Throughout 2026, Embecta generated roughly $261 million in income, reflecting a 0.3% decline year-over-year on an as-reported foundation or a 2% decline on an adjusted fixed forex foundation. These outcomes had been largely in step with our expectations, pushed by efficiency inside our worldwide enterprise. Inside the US, income for the quarter totaled roughly $131 million, reflecting a year-over-year decline of seven.6% on an adjusted fixed forex foundation.
The decline was pushed by a mix of decrease pricing in addition to decrease volumes reflecting channel dynamics. This was considerably offset by order timing. Turning to our worldwide enterprise, income for the primary quarter totaled roughly $130 million, representing a rise of 8.4% on a reported foundation and a rise of 4.6% on an adjusted fixed forex foundation. This efficiency was pushed by power throughout EMEA and Latin America. Whereas China remained a headwind within the quarter, the outcomes there have been largely in step with our expectations. As we now have mentioned beforehand, we proceed to anticipate the restoration in China to be extra fiscal second-half weighted, given ongoing market dynamics and the broader geopolitical and commerce setting.
In the meantime, from a product household perspective through the quarter, adjusted fixed forex pen needle income declined roughly 4.4%, syringe income grew by roughly 5.3%, security product income grew roughly 7.3%, and contract manufacturing income declined roughly 16.7%. The year-over-year decline in pen needle income was primarily pushed by the identical components that impacted our US and China outcomes. This was partially offset by development inside EMEA and Latin America. Turning to our syringe merchandise, income elevated year-over-year pushed by improved efficiency inside Latin America, EMEA, and Asia, which greater than offset the continued declines within the US.
As we now have beforehand mentioned, US syringe revenues proceed to be impacted by long-term shifts in diabetes therapy in the direction of insulin pens, and this pattern stays in line with our expectations. Shifting to our security merchandise, delivered stable development within the quarter, pushed by beneficial properties throughout the US and EMEA. Lastly, contract manufacturing income that we generate by way of the manufacturing and gross sales of non-diabetes merchandise again to Becton Dickinson declined, as anticipated, as a result of continued insourcing of those merchandise by BD. Earlier than I flip the decision over to Jake, I might prefer to briefly contact upon our monetary steering for the yr. At present, we reaffirmed our beforehand supplied monetary steering ranges.
Nonetheless, we now anticipate to be nearer to the decrease finish of these steering ranges pushed by incremental US pricing headwinds. Considerably offsetting this incremental strain throughout the US is an improved outlook for our worldwide enterprise. With that, let me flip the decision over to Jake.
Jake Elguicze: Thanks, Dev. Good morning, everybody. Given the dialogue that has already occurred concerning income, I’ll begin my overview of Embecta’s first quarter monetary efficiency on the gross revenue line. GAAP gross revenue and margin for 2026 totaled $161.7 million and 61.9% respectively. This in comparison with $151.7 million and 60% within the prior yr interval. Whereas on an adjusted foundation, our Q1 2026 adjusted gross revenue and margin totaled $163.5 million and 62.6%. This in comparison with $164.2 million and 62.7% within the prior yr interval. The slight year-over-year decline in adjusted gross revenue and margin was primarily pushed by the unfavorable year-over-year pricing dynamics that Dev talked about earlier and blend.
These headwinds had been partially offset by manufacturing value enchancment packages and decrease manufacturing purposeful prices. Turning to GAAP working revenue and margin, throughout 2026, they had been $83.3 million and 31.9%. This in comparison with $28.7 million and 11% within the prior yr interval. Whereas on an adjusted foundation, our Q1 2026 adjusted working revenue and margin totaled $79.3 million and 30.4%. This in comparison with $80.5 million and 30.7% within the prior yr interval.
The small year-over-year lower in adjusted working revenue is primarily as a result of decline in adjusted gross revenue that I simply talked about coupled with a rise in R&D bills that’s related to quite a lot of initiatives underway on the firm together with the event of market-appropriate pen needles and syringes, the event of a pen injector, in addition to venture prices related to changing into cannula unbiased. This was partially offset by decrease year-over-year SG&A bills as a result of restructuring initiative we introduced mid final fiscal yr. Turning to the underside line, GAAP internet revenue and earnings per diluted share had been $44.1 million and $0.74 throughout 2026, as in comparison with zero within the prior yr interval.
Whereas on an adjusted foundation, throughout 2026, internet revenue and earnings per share had been $42.3 million and $0.71 as in comparison with $38.3 million and $0.65 within the prior yr interval. The rise in year-over-year adjusted internet revenue and diluted earnings per share is primarily as a result of a discount in curiosity expense in addition to a decrease year-over-year adjusted tax price pushed by tax planning actions. This was partially offset by the adjusted working revenue drivers I simply mentioned. Turning to the stability sheet and money move, throughout 2026, we generated roughly $17 million in free money move.
Moreover, we repaid roughly $38 million of excellent debt and additional diminished our final twelve months internet leverage degree to roughly 2.8 occasions, as outlined beneath our credit score facility settlement in comparison with our covenant requirement of beneath 4.75 occasions. That completes my ready remarks on our first quarter 2026. Subsequent, I wish to focus on our 2026 monetary steering and sure underlying assumptions. Starting with income, on an adjusted fixed forex foundation, we’re reaffirming our beforehand supplied steering vary which known as for income to be flat to down 2% as in comparison with 2025 ranges.
Turning to our ideas on FX, we’re reaffirming our beforehand supplied steering which known as for overseas forex to be a tailwind of roughly 1.2% throughout 2026. Likewise, we’re reaffirming our beforehand supplied steering related to the Italian payback measure of an estimated 0.1% year-over-year headwind. On a mixed foundation, our as-reported income steering continues to name for a variety of between detrimental 0.9% to constructive 1.1%, leading to a income information of between $1.071 billion and $1.093 billion. As Dev beforehand talked about, we at present anticipate that we’ll be nearer to the decrease finish of that vary.
Turning to adjusted working margin and adjusted diluted earnings per share, we’re additionally reaffirming these beforehand supplied steering ranges of between 29-30% for adjusted working margin and for between $2.80 and $3 by way of adjusted EPS. Like my feedback concerning our expectations regarding income, we at present anticipate to be nearer to the decrease finish of these ranges due to the incremental headwinds we at the moment are anticipating throughout the US through the first half of the yr.
Turning to the stability sheet and money move, we proceed to anticipate that in 2026, we’ll repay roughly $150 million in debt and that we are going to generate between $180 million and $200 million in free money move, though nearer to the low finish of that vary. And at last, earlier than I flip the decision over to the operator, I might like to focus on some concerns concerning the cadence of quarterly income expectations throughout 2026. Shifting ahead, we could not present any additional commentary in regards to the quarterly cadence of income on an ongoing foundation.
Throughout fiscal yr 2025, we generated roughly 48% of our adjusted income {dollars} through the first half of the yr, and roughly 52% of our adjusted income {dollars} through the second half of the yr. Throughout fiscal yr 2026, we beforehand anticipated an analogous cadence of income efficiency. At the moment, we anticipate to generate roughly 46% of our adjusted income {dollars} through the first half of the yr and roughly 54% of our adjusted income {dollars} through the second half of the yr. As in comparison with our preliminary expectations, the decrease anticipated income within the first half is pushed by buyer combine, aggressive depth, and channel dynamics inside our US enterprise.
In the meantime, we now anticipate the second half of the yr to be higher than beforehand anticipated as a result of a continuation of the power of efficiency internationally. That completes my ready remarks. And right now, I wish to flip the decision over to the operator for questions. Operator?
Operator: Thanks. In case your query has been answered and also you’d prefer to take away your self from the queue, please press 11 once more.
Marie Thibault: Our first query comes from Marie Thibault with BTIG. Your line is open.
Sam Huang: Hello, good morning. That is Sam on for Marie. Thanks for taking the questions right here. Devdatt Kurdikar and Jake Elguicze, possibly I can begin on the quarter and possibly extra of a deeper dive by way of the dynamics we noticed, whether or not it is distributor ordering, possibly what you are seeing in that US enterprise, the pricing impression that you simply’re now calling out. Volumes? After which additionally possibly a bit on China by way of the restoration within the again half that you simply’re anticipating?
Devdatt Kurdikar: Hey. Good morning, Sam. Good to talk with you this morning. So on the US, you realize, we noticed a year-over-year decline excluding CMA of about 7.4% and it was actually pushed by two components: decrease pricing and decrease quantity. However the decrease quantity was actually channel dynamics and a few contractual dynamics. On the pricing entrance, most likely the one largest issue was a special buyer and product combine than we had skilled in the identical quarter final yr. That impacted form of our internet pricing. And on the amount facet, we had channel dynamics that had been partially offset by superior buy forward of a value improve that we took on January 1. That is actually what was driving the US outcomes.
On China, as you keep in mind, China final yr was a big step down for us in ’25 versus ’24. As we navigated by way of the broader commerce setting and geopolitical dynamics, we put some initiatives in place in that enterprise, reorganizing our Salesforce, introducing a brand new pen needle over there that may go face to face with a few of the native branded firms. And people initiatives are gaining traction. On this quarter, Q1, our efficiency in China was in step with our expectations for the quarter. Now actually, as we undergo the yr, we’re anticipating some restoration within the second half of the yr.
For the primary half of the yr, China shall be a headwind as we have a look at our year-over-year efficiency. After which for the second half of the yr, possibly much less so. Something you want so as to add?
Jake Elguicze: Yeah. Sam, I believe in case you simply zoom out for a second, I believe in case you recall, I believe our preliminary steering for the primary quarter income known as for us to generate roughly 24% of our full-year as-reported income {dollars} through the first quarter. That will have equated to a variety of someplace between $257 million and $262 million. So the quarter largely performed out as we anticipated, coming in nearer to the upper finish of that beforehand supplied income vary. I believe, importantly, volumes proceed to be constructive, notably exterior of the US. Quantity power in EMEA and Latin America actually really exceeded our inner expectations.
To Devdatt Kurdikar’s level, I believe, actually, the merchandise that was a slight incremental headwind as in comparison with our preliminary information was a few of the pricing dynamics that occurred due to simply the marginally totally different buyer combine, if you’ll, and form of as in comparison with our unique ideas. However absent that, the quarter performed out from a income standpoint in addition to the remainder of the P&L actually just about largely as we anticipated.
Sam Huang: Yeah. Very useful. Recognize the main points, guys. Perhaps only a fast follow-up. Devdatt Kurdikar, you talked about the brand new oral GLP-1s which can be beginning to roll out at this level. Clearly, there’s a spot for injectables additionally. So possibly you possibly can lay out what offers you or why injectables nonetheless have a spot on this broader market with new orals now in place? Thanks.
Devdatt Kurdikar: Completely, Sam. We stay tremendous excited in regards to the GLP-1 alternative. Clearly, we have been following the event within the oral GLP-1 area. And I do wish to observe that the launches in calendar yr 2026 had been anticipated, and we had included assumptions for them once we calculated the $100 million-plus income alternative. Based mostly on the information we now have, injectables have a greater weight reduction profile than orals.
Definitely, in keeping with the market analysis experiences we have learn and a few press experiences, it seems, and clearly, that is early days, that the potential use circumstances for orals are for sufferers who might need an aversion to needles, possibly in geographies the place there may be restricted chilly storage and transport amenities, after which lastly, possibly as upkeep remedy for individuals who wish to get off injectables. It seems, once more, that primarily based on the early learn on the prescriptions for the oral up to now, that a lot of the sufferers who’re utilizing orals are new to the remedy. So it form of factors to market enlargement. So that is all in step with what we had assumed.
I additionally wish to level out that, actually for the most important drug firms which can be within the GLP-1 area, we have a look at their pipelines, and a lot of the medication which can be in growth of their pipelines themselves are all injectable medication. And look, extra lately, there was some extra incremental constructive traction for us within the GLP-1 alternative. We learn with curiosity that Zepbound within the US was an auto-injector, has gotten approval for a QuickPen. Clearly, if that drug will get delivered by way of pen, sufferers are going to wish pen needles. We’ve got a powerful place within the US, so actually we’ll do our greatest to capitalize on the chance.
So for all these causes, regardless of a few of the latest press on oral GLPs, we stay very, very assured within the GLP-1 alternative for us.
Sam Huang: Is smart. Thanks a lot for taking the questions.
Operator: Thanks. And our subsequent query comes from Travis Steed with Financial institution of America Securities. Your line is open.
Gracia Leydon Mahoney: Hey. That is Gracia on for Travis. I needed to follow-up possibly on the power within the worldwide this quarter. You known as out EMEA and Latin America. Simply form of needed to see particularly any extra coloration on what improved versus Outlook three months in the past and offers you the arrogance and visibility there that power continued all through the remainder of the yr.
Devdatt Kurdikar: Yeah. Look. In two phrases, it is simply superior execution. I believe notably in Latin America, our group over there may be driving development. They’ve received a brand new buyer over. That is a big buyer that is driving development as properly. So actually, it isn’t one single issue, Gracia. I’d level to only good execution by our group in these areas.
Gracia Leydon Mahoney: Nice. After which possibly only one follow-up on the pricing headwind. Any solution to form of quantify that incremental headwind that you simply’re seeing and possibly what’s baked in on the highest finish and low finish of the information with reference to that now since these dynamics have modified round?
Jake Elguicze: Certain, Gracia. That is Jake. I believe, in our ready remarks, we talked about how we predict that we will be nearer to the decrease finish of the income steering vary as a result of incremental pricing headwinds. And in case you recall, the unique steering that we had on the excessive finish and the low finish known as for our manufacturing income year-over-year to be down about 50 foundation factors. That is actually unchanged proper now by way of the present information. From a quantity standpoint, the excessive finish of the information known as for volumes to be down about 50 foundation factors. The low finish of the information beforehand known as for volumes to be down about 150 foundation factors.
Internet proper now, we really suppose that volumes year-over-year, I believe, importantly, are coming in a bit bit stronger there. And proper now, the present information requires volumes to form of be flattish year-over-year. And largely, I’d say, relative stability by way of the US marketplace for the total yr. And by way of worldwide, an improved outlook internationally as in comparison with the unique information. So I believe volumes remaining secure now as in comparison with, say, beforehand on the mid we might have known as for a few 1% headwind. When it comes to new merchandise, the low finish of the information beforehand known as for form of flattish contribution from new merchandise.
The excessive finish of the information known as for about 1% development year-over-year coming from new merchandise. And proper now, I believe the present information requires constructive contribution of about 50 foundation factors. So, basically, proper now, form of the brand new product contribution being round 50 foundation factors form of offsetting these contract manufacturing headwinds of about 50 foundation factors, the core volumes being comparatively flattish, and proper now, simply given a few of the more moderen pricing dynamics impacting the US enterprise, that is actually what’s inflicting us now to be nearer to the decrease finish of our present steering vary. As in comparison with beforehand once we initially supplied steering, we thought that pricing was largely going to be flat year-over-year.
Gracia Leydon Mahoney: Nice. Thanks.
Operator: Our subsequent query comes from Ryan Schiller with Wolfe Analysis. Your line is open.
Ryan Schiller: Good morning. Thanks for taking my query. I wish to click on on the auto-injector venture. Are you able to give us an concept of how lengthy one thing like this takes and when this would possibly put {dollars} on the board? And any feedback on TAM or market sizing can be a lot appreciated.
Devdatt Kurdikar: Yeah. Ryan, first off, you realize, it is the pen injector venture that we began. Look, we’re within the early phases. I strongly imagine we now have the R&D capabilities, the manufacturing capabilities, actually to develop the product. And given the relationships we have established now with the generic drug firms, we actually have the channel now to current that product. It is means too early for me to speak about timing and market sizing, however actually because the venture develops and evolves, we’ll actually be talking extra about that.
Ryan Schiller: Thanks. After which only one extra for me on the GLP-1 alternative. So that you mentioned this has a $100 million income by 2033 on the Investor Day. The information appears to incorporate roughly $10 million for 2026. Can you set any finer factors on what the penetration curve would possibly appear like to achieve that $100 million of income?
Devdatt Kurdikar: Yeah. So possibly simply to form of remind all people what was included in that $100 million. Proper? So what we did once we calculated that’s, clearly, we had an estimate for the variety of sufferers on GLP-1s. We diminished that by an estimate for what number of sufferers can be on oral, regardless that the present indications, whereas early days, are that orals are increasing the market relatively than pulling sufferers away from injectables. We solely checked out weight problems and diabetes indications. We didn’t consider different indications that we all know pharma firms are pursuing. We factored in solely reimbursement as was obtainable then, virtually a yr in the past. Clearly, reimbursement has expanded. Costs have come down.
After which lastly, within the assumptions that we made, we assumed that the supply format that was in place then would stay form of static. Significantly within the US, Mounjaro and Zepbound pens would proceed to be obtainable solely in injector all by way of this era. However as I famous earlier, we learn with curiosity that Lilly does have FDA approval for his or her QuickPen. And I imagine has commented that they anticipate to be launching this within the coming weeks or so. So all of those are potential upsides to the $100 million. As well as, we lately began discussions with branded pharma firms for medication in growth the place they might want a pen needle for his or her medication.
That is not included of their estimate as properly. So all these causes give us confidence that the $100 million-plus alternative continues to be actual. And over the previous 9 months since we spoke about it publicly, our confidence has solely elevated. With respect to timing, a lot of the timing goes to be pushed by patent expirations. So in 2026, we and our companions proceed to anticipate that China, India, Brazil, Canada would possibly see generic launches. I discussed in my remarks that in India, a few firms have already gotten approval and have talked publicly about launching generic semaglutide in 2026. Canada continues to be anticipated to get approval someday this yr.
In China, our firms are working with native Chinese language firms which can be focused on launching generic GLP-1s. So I’d say that the ramp-up to that $100 million-plus goes to be pushed largely by patent expirations. As a result of actually, nearly all of firms that wish to launch generic semaglutide in any area of the world are in discussions with us, both on the company degree or with our native group.
Ryan Schiller: Thanks.
Operator: This concludes our query and reply session. I might like to show the decision again over to Devdatt Kurdikar for closing remarks.
Devdatt Kurdikar: As we shut the decision, I wish to thank my colleagues throughout Embecta for his or her continued focus and execution. We’re working in an setting marked by heightened competitors and an evolving geopolitical and commerce backdrop, and the group continues to reply with self-discipline and resilience. As we transfer by way of fiscal yr 2026, our priorities stay clear. We’re centered on our objectives of strengthening our core franchise, advancing our focused development initiatives, and sustaining sturdy profitability and money move to assist the strategic commitments we outlined at our Analyst and Investor Day. Thanks for becoming a member of us right this moment and to your continued curiosity in Embecta.
Operator: Thanks to your participation. It’s possible you’ll now disconnect. Everybody, have a terrific day.
Before you purchase inventory in Embecta, take into account this:
The Motley Idiot Inventory Advisor analyst group simply recognized what they imagine are the 10 finest shares for traders to purchase now… and Embecta wasn’t one among them. The ten shares that made the reduce may produce monster returns within the coming years.
Take into account when Netflix made this listing on December 17, 2004… in case you invested $1,000 on the time of our suggestion, you’d have $432,297!* Or when Nvidia made this listing on April 15, 2005… in case you invested $1,000 on the time of our suggestion, you’d have $1,067,820!*
Now, it’s price noting Inventory Advisor’s complete common return is 894% — a market-crushing outperformance in comparison with 194% for the S&P 500. Do not miss the most recent prime 10 listing, obtainable with Inventory Advisor, and be a part of an investing group constructed by particular person traders for particular person traders.
See the ten shares »
*Inventory Advisor returns as of February 5, 2026.
This text is a transcript of this convention name produced for The Motley Idiot. Whereas we attempt for our Silly Greatest, there could also be errors, omissions, or inaccuracies on this transcript. As with all our articles, The Motley Idiot doesn’t assume any accountability to your use of this content material, and we strongly encourage you to do your personal analysis, together with listening to the decision your self and studying the corporate’s SEC filings. Please see our Phrases and Circumstances for extra particulars, together with our Compulsory Capitalized Disclaimers of Legal responsibility.
The Motley Idiot has no place in any of the shares talked about. The Motley Idiot has a disclosure coverage.
Embecta (EMBC) Q1 2026 Earnings Name Transcript was initially revealed by The Motley Idiot